RAPID: The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery

Sponsor
Medical University of Vienna (Other)
Overall Status
Recruiting
CT.gov ID
NCT05331027
Collaborator
(none)
190
1
2
29
6.5

Study Details

Study Description

Brief Summary

Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching a modified Aldrete score ≥ 12, as compared to sevoflurane in patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery.

Detailed Description

Background: Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching amodified Aldrete score ≥ 12, as compared to sevoflurane in patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery.

Methods: The investigators will include 190 patients ≥ 65 years of age undergoing minor-to moderate-risk noncardiac surgery in this randomized, double-blinded clinical trial. Patients will be randomly assigned to receive desflurane or sevoflurane throughout surgery for maintenance of anesthesia. The primary outcome will be the time between discontinuation of desflurane until full postoperative recovery assessed via consecutive Aldrete Score assessments in the first 90 minutes after arrival at PACU. Aldrete Score will be assessed upon arrival at PACU and thereafter in five-minute intervals.

Statistics: The primary outcome, the time from discontinuation of volatile anesthetic agent to reaching discharge criteria from PACU assessed via Aldrete Score values,will be compared between both study groups using a Mann-Whitney-U test. Furthermore, the investigators will perform a median regression model for time to Aldrete score ≥ 12 points accounting for group as a factor as well as further covariables e.g. age, gender, weight.

Level of originality: Data regarding the effects of general anesthesia using desflurane in comparison to sevoflurane on postoperative recovery are mainly available from small studies. So far, there is very limited data on postoperative recovery and neurocognitive rehabilitation in elderly patients. However, this patient population is at a higher risk of developing postoperative neurocognitive complications, and could therefore, profit from a more rapid resurgence from anesthesia and postoperative recovery. Moreover, outpatient surgery will be becoming even more important. Therefore, reduction in postoperative PACU stay in combination with a decreased risk to develop postoperative delirium or cognitive dysfunction, might therefore improve outcome in this patient population as well.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
190 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery in Patients Undergoing Minor- to Moderate-risk Noncardiac Surgery - a Prospective Double-blinded Randomized Clinical Trial
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
May 31, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Desflurane Group

After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.

Drug: Desflurane
After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.

Active Comparator: Sevoflurane Group

After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.

Drug: Sevoflurane
After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.

Outcome Measures

Primary Outcome Measures

  1. Modified Aldrete Score [Consecutive measurements until reaching 12 points for a maximum of 90 minutes after surgery and reaching PACU.]

    A score to assess readiness of discharge from postanesthesia care unit (PACU). Patients can achieve 0-14 points in the modified Aldrete Score. A modified Aldrete Score > 12 points signals that criteria for discharge from PACU have been fulfilled, a modified Aldrete Score < 12 points signals that patients should stay in PACU.

Secondary Outcome Measures

  1. Secondary Outcome 1: Number of liters of supplemental oxygen administered in PACU for SpO2 ≥ 93% [Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.]

    Postoperative need for administration of supplemental oxygen to maintain a SpO2 of ≥ 93% during PACU stay

  2. Secondary Outcome 2: Postoperative cerebral oxygen saturation [Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.]

    Postoperative non-invasive near-infrared spectroscopy for measurement of cerebral oxygenation

  3. Secondary Outcome 3: Postoperative bispectral index values [Until reaching 12 points of the modified Aldrete score for a maximum of 90 minutes after surgery and reaching PACU.]

    Postoperative continuous measurement of bispectral index for detection of postoperative aftereffects of anesthesia on awareness

  4. Secondary Outcome 4: Ready for Hospital Discharge Scale Scores [For the first three postoperative days]

    A score to evaluate patients' subjective readiness for hospital discharge. Patients can achieve 0-80 points in the Ready for Hospital Discharge Scale. Higher scores mean that patients are ready for hospital discharge, lower scores mean that patients are not ready for hospital discharge.

Other Outcome Measures

  1. Tertiary Outcome 1: NT-proBNP [Within the first two postoperative days]

    Maximum concentrations of NT-proBNP

  2. Tertiary Outcome 2: Troponin T [Within the first two postoperative days]

    Maximum concentrations of Troponin T

  3. Tertiary Outcome 3: Copeptin [Within the first two postoperative days]

    Maximum concentrations of Copeptin

  4. Tertiary Outcome 4: Interleukin-6 [Within the first two postoperative days]

    Maximum concentrations of Interleukin-6

  5. Tertiary Outcome 5: Procalcitonin [Within the first two postoperative days]

    Maximum concentrations of Procalcitonin

  6. Tertiary Outcome 6: CRP [Within the first two postoperative days]

    Maximum concentrations of CRP

  7. Tertiary Outcome 7: S100-B [Within the first two postoperative days]

    Maximum concentration of S-100B

  8. Exploratory Outcome 8: Delirium [For the first three postoperative days]

    3D-CAM questionnaires for the evaluation of postoperative delirium. Patients can achieve 0-22 points in the 3D-CAM questionnaire. Higher scores indicate confusion, lower scores indicate no confusion.

  9. Exploratory Outcome 9: Postoperative cognitive dysfunction [30 days after surgery]

    Montreal cognitive assessments for the evaluation of long-term postoperative cognitive dysfunction. Patients can achieve 0-22 points in the Montreal cognitive assessment. A reduction of 2 points from baseline indicates postoperative cognitive dysfunction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 95 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥ 65 years of age at time of surgery

  • Scheduled for elective minor- to moderate-risk noncardiac surgery with expected time of surgery ≤ 2 hours

Exclusion Criteria:
  • Patients undergoing emergency surgery

  • Patients undergoing bariatric surgery

  • History of documented dementia / neurologic disorder

  • Language, vision, or hearing impairments that may compromise cognitive assessments

  • History of malignant hyperthermia

  • History of structural muscle disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of Vienna Vienna Austria 1100

Sponsors and Collaborators

  • Medical University of Vienna

Investigators

  • Principal Investigator: Christian Reiterer, MD, Medical University of Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christian Reiterer, Principal Investigator, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT05331027
Other Study ID Numbers:
  • RAPID_01
First Posted:
Apr 15, 2022
Last Update Posted:
Jul 29, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Christian Reiterer, Principal Investigator, Medical University of Vienna
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2022